

+

 $+$ 

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Application Number	Not known 10/749,832
Filing Date	Herewith
First Named Inventor	Redl, Heinz
Group Art Unit	Not yet known
Examiner Name	Not yet known
Attorney Docket Number	20695C-003420US

*(use as many sheets as necessary)*

Sheet	1	of	3
-------	---	----	---

Class / subclass

[illegible]

→ Goldenberg

Class/Subclass

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>o</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
RL	B1	CA	1 168 982		Redl et al.	6-12-1984	—	
RL	B2	EPO	EP 0 292 472 B1		Redl et al.	5-19-1988	—	
RL	B3	PCT	WO 98/43686	A1	Hubbell	10-8-1998	—	

**Examiner  
Signature**

Jeffrey E. Russell

Date Considered

February 14 2005

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

60106963 v1

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Not yet known 10/749,832
		Filing Date	Herewith
		First Named Inventor	Redl, Heinz
		Group Art Unit	Not yet known
		Examiner Name	Not yet known
Sheet 2 of 3	Attorney Docket Number	20695C-003420US	

FOREIGN PATENT DOCUMENTS								Class/Subclass
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (If known)				
JR	B4	PCT	WO 01/10479	A1	Stark et al.	2-15-2001	—	
JR	B5	PCT	WO-96/06641-A1		Prizm Pharm.	03-1996	—	
JR	B6	PCT	WO-99/40947-A2		Resolution Pharm.	08-1999	—	

Examiner Signature	Jeffrey E. Russell	Date Considered	February 14, 2005
-----------------------	--------------------	--------------------	-------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
60106963 v1

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	Not yet known 10/749832
		Filing Date	Herewith
		First Named Inventor	Redl, Heinz
		Group Art Unit	Not yet known
		Examiner Name	Not yet known
Sheet	3	of	3
		Attorney Docket Number	20695C-003420US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JRL	C1	FRANK et al., "Leptin enhances wound re-epithelialization and constitutes a direct function of leptin in skin repair," <i>The Journal of Clinical Investigation</i> , 106(4):501-509 (2000)	
JRL	C2	HOUCK et al., "Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms," <i>The Journal of Biological Chemistry</i> , 267(36):26031-26037 (1992)	
JRL	C3	KUROKAWA, et al. "Enhanced Fibrinolysis by a Bispecific Monoclonal Antibody Reactive to Fibrin and Tissue Plasminogen Activator" <i>Biotechnology</i> , 7:1163-1167 (November 1989)	
JRL	C4	MARKLAND et al., "Iterative Optimization of High-Affinity Protease Inhibitors Using Phase Display, 1. Plasmin," <i>Biochemistry</i> , 35:8045-8057 (1996)	
JRL	C5	SAHNI et al., "Vascular Endothelial Growth Factor Binds to Fibrinogen and Fibrin and Stimulates Endothelial Cell Proliferation" <i>Blood</i> , 96:3772-3778 (2000)	
JRL	C6	SIERRA-HONIGMANN et al., "Biological Action of Leptin as an Angiogenic Factor," <i>Science</i> , 281:1683-1686 (1998)	
JRL	C7	TISCHER et al., "The Human Gene for Vascular Endothelial Growth Factor," <i>Journal of Biological Chemistry</i> , 266(18):11947-11954 (1991)	

60106963 v1

Examiner Signature	Jeffrey E. Russell	Date Considered	February 14, 2005
-----------------------	--------------------	--------------------	-------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60106963 v1